BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 23786773)

  • 1. The DREAM complex mediates GIST cell quiescence and is a novel therapeutic target to enhance imatinib-induced apoptosis.
    Boichuk S; Parry JA; Makielski KR; Litovchick L; Baron JL; Zewe JP; Wozniak A; Mehalek KR; Korzeniewski N; Seneviratne DS; Schöffski P; Debiec-Rychter M; DeCaprio JA; Duensing A
    Cancer Res; 2013 Aug; 73(16):5120-9. PubMed ID: 23786773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imatinib mesylate induces quiescence in gastrointestinal stromal tumor cells through the CDH1-SKP2-p27Kip1 signaling axis.
    Liu Y; Perdreau SA; Chatterjee P; Wang L; Kuan SF; Duensing A
    Cancer Res; 2008 Nov; 68(21):9015-23. PubMed ID: 18974147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The DREAM complex in antitumor activity of imatinib mesylate in gastrointestinal stromal tumors.
    DeCaprio JA; Duensing A
    Curr Opin Oncol; 2014 Jul; 26(4):415-21. PubMed ID: 24840522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone H2AX is a mediator of gastrointestinal stromal tumor cell apoptosis following treatment with imatinib mesylate.
    Liu Y; Tseng M; Perdreau SA; Rossi F; Antonescu C; Besmer P; Fletcher JA; Duensing S; Duensing A
    Cancer Res; 2007 Mar; 67(6):2685-92. PubMed ID: 17363589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug repurposing identifies a synergistic combination therapy with imatinib mesylate for gastrointestinal stromal tumor.
    Pessetto ZY; Ma Y; Hirst JJ; von Mehren M; Weir SJ; Godwin AK
    Mol Cancer Ther; 2014 Oct; 13(10):2276-87. PubMed ID: 25122069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role for the proapoptotic factor BIM in mediating imatinib-induced apoptosis in a c-KIT-dependent gastrointestinal stromal tumor cell line.
    Gordon PM; Fisher DE
    J Biol Chem; 2010 May; 285(19):14109-14. PubMed ID: 20231287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased KIT inhibition enhances therapeutic efficacy in gastrointestinal stromal tumor.
    Kim TS; Cavnar MJ; Cohen NA; Sorenson EC; Greer JB; Seifert AM; Crawley MH; Green BL; Popow R; Pillarsetty N; Veach DR; Ku AT; Rossi F; Besmer P; Antonescu CR; Zeng S; Dematteo RP
    Clin Cancer Res; 2014 May; 20(9):2350-62. PubMed ID: 24583793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
    Croom KF; Perry CM
    Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic effect of imatinib in gastrointestinal stromal tumors: AKT signaling dependent and independent mechanisms.
    Tarn C; Skorobogatko YV; Taguchi T; Eisenberg B; von Mehren M; Godwin AK
    Cancer Res; 2006 May; 66(10):5477-86. PubMed ID: 16707477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autophagy inhibition and antimalarials promote cell death in gastrointestinal stromal tumor (GIST).
    Gupta A; Roy S; Lazar AJ; Wang WL; McAuliffe JC; Reynoso D; McMahon J; Taguchi T; Floris G; Debiec-Rychter M; Schoffski P; Trent JA; Debnath J; Rubin BP
    Proc Natl Acad Sci U S A; 2010 Aug; 107(32):14333-8. PubMed ID: 20660757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53 modulation as a therapeutic strategy in gastrointestinal stromal tumors.
    Henze J; Mühlenberg T; Simon S; Grabellus F; Rubin B; Taeger G; Schuler M; Treckmann J; Debiec-Rychter M; Taguchi T; Fletcher JA; Bauer S
    PLoS One; 2012; 7(5):e37776. PubMed ID: 22662219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-KIT monoclonal antibody inhibits imatinib-resistant gastrointestinal stromal tumor growth.
    Edris B; Willingham SB; Weiskopf K; Volkmer AK; Volkmer JP; Mühlenberg T; Montgomery KD; Contreras-Trujillo H; Czechowicz A; Fletcher JA; West RB; Weissman IL; van de Rijn M
    Proc Natl Acad Sci U S A; 2013 Feb; 110(9):3501-6. PubMed ID: 23382202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic induction of apoptosis by the Bcl-2 inhibitor ABT-737 and imatinib mesylate in gastrointestinal stromal tumor cells.
    Reynoso D; Nolden LK; Yang D; Dumont SN; Conley AP; Dumont AG; Zhou K; Duensing A; Trent JC
    Mol Oncol; 2011 Feb; 5(1):93-104. PubMed ID: 21115411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early effects of imatinib mesylate on the expression of insulin-like growth factor binding protein-3 and positron emission tomography in patients with gastrointestinal stromal tumor.
    Trent JC; Ramdas L; Dupart J; Hunt K; Macapinlac H; Taylor E; Hu L; Salvado A; Abbruzzese JL; Pollock R; Benjamin RS; Zhang W
    Cancer; 2006 Oct; 107(8):1898-908. PubMed ID: 16986125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Systematic Analysis of Negative Growth Control Implicates the DREAM Complex in Cancer Cell Dormancy.
    MacDonald J; Ramos-Valdes Y; Perampalam P; Litovchick L; DiMattia GE; Dick FA
    Mol Cancer Res; 2017 Apr; 15(4):371-381. PubMed ID: 28031411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological Inhibition of KIT Activates MET Signaling in Gastrointestinal Stromal Tumors.
    Cohen NA; Zeng S; Seifert AM; Kim TS; Sorenson EC; Greer JB; Beckman MJ; Santamaria-Barria JA; Crawley MH; Green BL; Rossi F; Besmer P; Antonescu CR; DeMatteo RP
    Cancer Res; 2015 May; 75(10):2061-70. PubMed ID: 25836719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gastrointestinal stromal tumors.
    Antonescu C
    Curr Top Microbiol Immunol; 2012; 355():41-57. PubMed ID: 22015552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistance to c-KIT kinase inhibitors conferred by V654A mutation.
    Roberts KG; Odell AF; Byrnes EM; Baleato RM; Griffith R; Lyons AB; Ashman LK
    Mol Cancer Ther; 2007 Mar; 6(3):1159-66. PubMed ID: 17363509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors.
    Tarn C; Rink L; Merkel E; Flieder D; Pathak H; Koumbi D; Testa JR; Eisenberg B; von Mehren M; Godwin AK
    Proc Natl Acad Sci U S A; 2008 Jun; 105(24):8387-92. PubMed ID: 18550829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Green tea (-)-epigalocatechin-3-gallate inhibits KIT activity and causes caspase-dependent cell death in gastrointestinal stromal tumor including imatinib-resistant cells.
    Chi HT; Vu HA; Iwasaki R; Thao le B; Hara Y; Taguchi T; Watanabe T; Sato Y
    Cancer Biol Ther; 2009 Oct; 8(20):1934-9. PubMed ID: 19770581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.